Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094249405> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2094249405 endingPage "955" @default.
- W2094249405 startingPage "955" @default.
- W2094249405 abstract "To the editor:We read with interest the recent paper by Polasek et al. on the evaluation of zolpidem as a mechanism-based inactivator of human CYP3A in vitro that was accompanied by the assessment of its metabolic interaction potential with CYP3A drugs [1]. The article clearly points out the mechanism of inactivation of human CYP3A in vitro and describes the implications of this mechanism for the in vivo metabolic interactions involving CYP3A. Given the prescription rate of zolpidem, this issue is of vital importance in terms of the drug’s efficacy and patients’ safety.However, one issue that was not addressed in the discussion of this interesting paper is that of the association between the patient’s sex and the endocrine specificity of zolpidem—as if zolpidem pharmacokinetics is a gender-independent factor. Based on current knowledge, the pharmacokinetics of zolpidem seems to be related to endocrine factors associated with CYP3A4 metabolism. As such, low plasma concentrations of free testosterone may contribute to lower CYP3A activity, with women achieving up to 50% higher zolpidem plasma levels, while exposure to testosterone activates the biotransformation via CYP3A [2]. This effect is conspicuous in the relative higher incidence of adverse drug reactions with zolpidem in women [3].The conclusions of the study reported in the paper are valid for the model study on male subjects. It would have been interesting, however, if the discussion were to have included the exciting element of endocrine-related differences in zolpidem action." @default.
- W2094249405 created "2016-06-24" @default.
- W2094249405 creator A5016768440 @default.
- W2094249405 creator A5046572324 @default.
- W2094249405 creator A5064774107 @default.
- W2094249405 creator A5070339940 @default.
- W2094249405 date "2010-06-16" @default.
- W2094249405 modified "2023-10-16" @default.
- W2094249405 title "Zolpidem pharmacokinetics and pharmacodynamics in metabolic interactions involving CYP3A: sex as a differentiating factor" @default.
- W2094249405 cites W2032506978 @default.
- W2094249405 cites W2044030218 @default.
- W2094249405 cites W2169843481 @default.
- W2094249405 doi "https://doi.org/10.1007/s00228-010-0854-x" @default.
- W2094249405 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2921491" @default.
- W2094249405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20552178" @default.
- W2094249405 hasPublicationYear "2010" @default.
- W2094249405 type Work @default.
- W2094249405 sameAs 2094249405 @default.
- W2094249405 citedByCount "19" @default.
- W2094249405 countsByYear W20942494052012 @default.
- W2094249405 countsByYear W20942494052014 @default.
- W2094249405 countsByYear W20942494052015 @default.
- W2094249405 countsByYear W20942494052017 @default.
- W2094249405 countsByYear W20942494052018 @default.
- W2094249405 countsByYear W20942494052020 @default.
- W2094249405 countsByYear W20942494052021 @default.
- W2094249405 countsByYear W20942494052022 @default.
- W2094249405 countsByYear W20942494052023 @default.
- W2094249405 crossrefType "journal-article" @default.
- W2094249405 hasAuthorship W2094249405A5016768440 @default.
- W2094249405 hasAuthorship W2094249405A5046572324 @default.
- W2094249405 hasAuthorship W2094249405A5064774107 @default.
- W2094249405 hasAuthorship W2094249405A5070339940 @default.
- W2094249405 hasBestOaLocation W20942494051 @default.
- W2094249405 hasConcept C111113717 @default.
- W2094249405 hasConcept C112705442 @default.
- W2094249405 hasConcept C11824378 @default.
- W2094249405 hasConcept C126322002 @default.
- W2094249405 hasConcept C2777123777 @default.
- W2094249405 hasConcept C2781210498 @default.
- W2094249405 hasConcept C526171541 @default.
- W2094249405 hasConcept C62231903 @default.
- W2094249405 hasConcept C71924100 @default.
- W2094249405 hasConcept C98274493 @default.
- W2094249405 hasConceptScore W2094249405C111113717 @default.
- W2094249405 hasConceptScore W2094249405C112705442 @default.
- W2094249405 hasConceptScore W2094249405C11824378 @default.
- W2094249405 hasConceptScore W2094249405C126322002 @default.
- W2094249405 hasConceptScore W2094249405C2777123777 @default.
- W2094249405 hasConceptScore W2094249405C2781210498 @default.
- W2094249405 hasConceptScore W2094249405C526171541 @default.
- W2094249405 hasConceptScore W2094249405C62231903 @default.
- W2094249405 hasConceptScore W2094249405C71924100 @default.
- W2094249405 hasConceptScore W2094249405C98274493 @default.
- W2094249405 hasIssue "9" @default.
- W2094249405 hasLocation W20942494051 @default.
- W2094249405 hasLocation W20942494052 @default.
- W2094249405 hasLocation W20942494053 @default.
- W2094249405 hasLocation W20942494054 @default.
- W2094249405 hasOpenAccess W2094249405 @default.
- W2094249405 hasPrimaryLocation W20942494051 @default.
- W2094249405 hasRelatedWork W1491964893 @default.
- W2094249405 hasRelatedWork W1556453740 @default.
- W2094249405 hasRelatedWork W2124344079 @default.
- W2094249405 hasRelatedWork W2148894622 @default.
- W2094249405 hasRelatedWork W2157262647 @default.
- W2094249405 hasRelatedWork W2227061539 @default.
- W2094249405 hasRelatedWork W2400119402 @default.
- W2094249405 hasRelatedWork W2594910449 @default.
- W2094249405 hasRelatedWork W2992709639 @default.
- W2094249405 hasRelatedWork W4311744554 @default.
- W2094249405 hasVolume "66" @default.
- W2094249405 isParatext "false" @default.
- W2094249405 isRetracted "false" @default.
- W2094249405 magId "2094249405" @default.
- W2094249405 workType "article" @default.